🏢 公司NewsroomGILDDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 10-15(美西日)仅日期·时区推断·⟳ 抓取 04:07:53回填·⚡ 决策 10-16 04:09:19·11.7 天前
吉利德宣布将于2026年10月29日盘后发布Q3财报，仅为日程通知无经营数据
该新闻稿是标准的财报日期/电话会安排通知，不含任何业绩、指引、产品或商业实质信息，对未来1-10个交易日的盈利预期无新增冲击，方向为中性，没有可交易的事件催化。
📄 原文GILD↗ 原文
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026…
不做 Gilead Sciences, Inc.（GILD.US）
纯财报日期/电话会日程通知，无业绩、指引、产品或订单等任何增量事实，方向中性、无edge；真正催化需等2026-10-29盘后实际财报，届时再研判
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
吉利德仅告知Q3财报将于10月29日盘后发布，无任何数字或指引变化；属于例行日程通知，不存在预期差，无可交易edge，故回避。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
关键理由
- 无——本次公告不含任何经营或财务增量事实，无法形成做多或做空逻辑
主要风险
- 真正的催化在10月29日财报本身（含指引与电话会），届时需依据实际数据重新研判，不应把日期通知当利好或利空提前下注
先例如何影响了这次决策
对本次决策的影响:未据此产生任何交易；等待10月29日实际财报再做事件研究
方向:不适用——财报日期预告为中性日程事件，历来不构成独立价格催化，无需以先例校准方向或幅度
涨幅量级:无实质增量信息，不存在可定价幅度
形态:无可评估的事件反应模式
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`gilead sciences q3 2026 financial results release date october 29 2026 webcast | 吉利德科学 2026年第三季度财报 发布时间 10月29日`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 1,284 字
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
A live webcast will be available in the Investors section of
www.gilead.com
and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at
www.gilead.com
, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
A live webcast will be available in the Investors section of
www.gilead.com
and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at
www.gilead.com
, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b2148b9324· 2026-10-16 04:09 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前